Innate Pharma Secures €15M Sanofi Investment

Innate Pharma SA has announced a €14,999,998.59 investment from Sanofi, as part of their ongoing collaboration. This capital increase is aligned with satisfactory market conditions and involves the subscription of 8,345,387 newly issued shares at €1.7974 per share. The initiative aims to bolster Innate's financial position for corporate purposes, extending its cash runway for pipeline execution and value creation.

The investment follows the 22nd resolution of Innate’s 2024 general meeting, with the closing anticipated on April 25, 2025. Post-closing, Sanofi will hold a 9.05% stake in Innate, ranking second among shareholders. The strategic move underlines Sanofi's commitment to advancing Innate’s BCMA targeting ANKET® program in autoimmune indications, further solidifying their partnership.